Ideas move science forward.

Most of the modern pharmacopoeia works imperfectly because of poor bioavailability, dose-limiting toxicity, unfavourable pharmacokinetics and regimens patients cannot sustain. Those constraints are rarely attributable to the underlying pharmacology, but to the chemistry constructed around it.

That distinction determines what is undertaken here. Each programme begins with an identified therapeutic deficiency and proceeds to the design of a novel molecular scaffold that resolves it while preserving the established clinical benefit. The same reasoning governs the delivery system, the formulation and, where required, the device.

Work here proceeds from that distinction, across four objectives: to contribute original ideas openly, on the reasoning that an idea held privately advances at the rate of a single laboratory; to treat the determinative endpoint as patient recovery rather than potency in an assay, which makes adherence, tolerability and route design parameters from the outset; to pursue indications for which no approved therapy exists, where scientific difficulty and absent investment reinforce one another; and to design the therapeutic agent and the system that delivers it as a single problem rather than two.

Important ideas often begin before they become a formal research programme, patent, publication or company. This platform provides a structured place to present those ideas and explain the reasoning behind them.